Cargando…
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
BRCA1 and BRCA2 both function in DNA double-strand break repair by homologous recombination (HR). Due to their HR defect, BRCA1/2-deficient cancers are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis), but they eventually acquire resistance. Preclinical studies yielded several PARPi resi...
Autores principales: | Bhin, Jinhyuk, Paes Dias, Mariana, Gogola, Ewa, Rolfs, Frank, Piersma, Sander R., de Bruijn, Roebi, de Ruiter, Julian R., van den Broek, Bram, Duarte, Alexandra A., Sol, Wendy, van der Heijden, Ingrid, Andronikou, Christina, Kaiponen, Taina S., Bakker, Lara, Lieftink, Cor, Morris, Ben, Beijersbergen, Roderick L., van de Ven, Marieke, Jimenez, Connie R., Wessels, Lodewyk F.A., Rottenberg, Sven, Jonkers, Jos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242444/ https://www.ncbi.nlm.nih.gov/pubmed/37209095 http://dx.doi.org/10.1016/j.celrep.2023.112538 |
Ejemplares similares
-
To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following
First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021) -
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
por: Annunziato, Stefano, et al.
Publicado: (2019) -
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
por: Barazas, Marco, et al.
Publicado: (2018) -
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition
por: Vos, Janet R, et al.
Publicado: (2019) -
Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts
por: Di Raimo, Tania, et al.
Publicado: (2020)